Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Stopped early · Phase 2

Conditions studied: Polycythemia Vera, Essential Thrombocythemia

In brief

This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.

Key facts

Study ID

NCT01998828

Run by

Sierra Oncology LLC - a GSK company

People needed

39

Starts

2014-02-19

Expected to finish

2015-05-07

Last updated by the study team

2020-04-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of either PV or ET as defined by the 2008 World Health Organization (WHO) Diagnostic Criteria
• Requires treatment for PV or ET, in the opinion of the study investigator
• Intolerant of, resistant to, or refuses current or available treatment for PV or ET
• Direct bilirubin ≤ 2.0 x upper limit of the normal range (ULN)
• Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN
• Calculated creatinine clearance (CrCl) of ≥ 45 mL/min
• Life expectancy > 24 weeks
• Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
• Females who are nursing must agree to discontinue nursing before the first dose of study drug
• Able to comprehend and willing to sign informed consent form

You may not qualify if…

• Prior splenectomy
• Uncontrolled intercurrent illness, per protocol
• Known positive status for human immunodeficiency virus (HIV)
• Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier
• Myeloproliferative neoplasm-directed therapy, other than aspirin, hydroxyurea, anagrelide, and/or phlebotomy, within 21 days prior to the first dose of study drug
• Anagrelide within 7 days prior to the first dose of study drug
• Presence of peripheral neuropathy ≥ Grade 2
• Unwilling or unable to take oral medication
• Prior use of a JAK1 or JAK2 inhibitor
• Use of strong CYP3A4 inducers within 1 week prior to the first dose of study drug
• QTc interval > 450 msec, unless attributed to bundle branch block

Where it is running

• Study site — Scottsdale, Arizona, United States
• Study site — Whittier, California, United States
• Study site — Tupelo, Mississippi, United States
• Study site — St Louis, Missouri, United States
• Study site — Houston, Texas, United States
• Study site — Frankston, Victoria, Australia
• Study site — Parkville, Victoria, Australia
• Study site — Vancouver, British Columbia, Canada
• Study site — Toronto, Ontario, Canada
• Study site — Montreal, Quebec, Canada
• Study site — La Tronche, France
• Study site — Nantes, France
• Study site — Paris, France
• Study site — Dresden, Germany
• Study site — Minden, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.